Rhythm Pharmaceuticals secures up to $750 million term loan led by KKR’s HealthCare Royalty with Blackstone
- Rhythm Pharmaceuticals entered a five-year $750 million term-loan facility led by KKR's HealthCare Royalty in partnership with Blackstone.
- The facility includes $500 million committed, with an initial $250 million draw expected at closing on November 6, 2026.
- Another $250 million of committed capital is available through June 30, 2028; an additional $250 million requires mutual agreement.
- Borrowings bear interest at SOFR plus 4.60%, with no scheduled principal amortization before maturity.
- Proceeds will support the amended LG Chem licensing agreement, global commercialization efforts and research and development programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611022159PRIMZONEFULLFEED9868824) on November 03, 2026, and is solely responsible for the information contained therein.